Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Fathi

Showing results (91-100 of 168) with videos related to

Pageof 17
Sort By:
Journal of Palliative Medicine|December 3, 2021
Factors Associated with Health Care Utilization at the End of Life for Patients with Acute Myeloid LeukemiaDagny M Vaughn, P Connor Johnson, Annemarie D Jagielo, et al.
Cancer|July 13, 2019
Outcomes for older adults with acute myeloid leukemia after an intensive care unit admissionSamuel D Slavin, Alyssa Fenech, Amanda L Jankowski, et al.
American Journal of Respiratory and Critical Care Medicine|November 2, 2017
Stakeholder Research Priorities for Smoking Cessation Interventions within Lung Cancer Screening Programs. An Official American Thoracic Society Research StatementHasmeena Kathuria, Frank C Detterbeck, Joelle T Fathi, et al.
Cancer|September 20, 2024
The American Cancer Society National Lung Cancer Roundtable strategic plan: Implementation of high-quality lung cancer screeningJoelle T Fathi, Angela M Barry, Grant M Greenberg, et al.
The Lancet. Oncology|October 21, 2021
Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trialCourtney D DiNardo, Andre C Schuh, Eytan M Stein, et al.
The Lancet. Haematology|March 29, 2023
Eprenetapopt combined with venetoclax and azacitidine in TP53-mutated acute myeloid leukaemia: a phase 1, dose-finding and expansion studyGuillermo Garcia-Manero, Aaron D Goldberg, Eric S Winer, et al.
Cancer|May 1, 2015
Health care utilization and end-of-life care for older patients with acute myeloid leukemiaAreej R El-Jawahri, Gregory A Abel, David P Steensma, et al.
Cancer|May 13, 2016
Phase 2 study of intensified chemotherapy and allogeneic hematopoietic stem cell transplantation for older patients with acute lymphoblastic leukemiaAmir T Fathi, Daniel J DeAngelo, Kristen E Stevenson, et al.
American Journal of Respiratory and Critical Care Medicine|October 1, 2020
Addressing Disparities in Lung Cancer Screening Eligibility and Healthcare Access. An Official American Thoracic Society StatementM Patricia Rivera, Hormuzd A Katki, Nichole T Tanner, et al.
Blood|May 5, 2018
High <i>NPM1</i>-mutant allele burden at diagnosis predicts unfavorable outcomes in de novo AMLSanjay S Patel, Frank C Kuo, Christopher J Gibson, et al.
Pageof 17

Showing results (91-100 of 168) with videos related to

Sort By:
Pageof 17
Journal of Palliative Medicine|December 3, 2021
Factors Associated with Health Care Utilization at the End of Life for Patients with Acute Myeloid LeukemiaDagny M Vaughn, P Connor Johnson, Annemarie D Jagielo, et al.
Cancer|July 13, 2019
Outcomes for older adults with acute myeloid leukemia after an intensive care unit admissionSamuel D Slavin, Alyssa Fenech, Amanda L Jankowski, et al.
American Journal of Respiratory and Critical Care Medicine|November 2, 2017
Stakeholder Research Priorities for Smoking Cessation Interventions within Lung Cancer Screening Programs. An Official American Thoracic Society Research StatementHasmeena Kathuria, Frank C Detterbeck, Joelle T Fathi, et al.
Cancer|September 20, 2024
The American Cancer Society National Lung Cancer Roundtable strategic plan: Implementation of high-quality lung cancer screeningJoelle T Fathi, Angela M Barry, Grant M Greenberg, et al.
The Lancet. Oncology|October 21, 2021
Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trialCourtney D DiNardo, Andre C Schuh, Eytan M Stein, et al.
The Lancet. Haematology|March 29, 2023
Eprenetapopt combined with venetoclax and azacitidine in TP53-mutated acute myeloid leukaemia: a phase 1, dose-finding and expansion studyGuillermo Garcia-Manero, Aaron D Goldberg, Eric S Winer, et al.
Cancer|May 1, 2015
Health care utilization and end-of-life care for older patients with acute myeloid leukemiaAreej R El-Jawahri, Gregory A Abel, David P Steensma, et al.
Cancer|May 13, 2016
Phase 2 study of intensified chemotherapy and allogeneic hematopoietic stem cell transplantation for older patients with acute lymphoblastic leukemiaAmir T Fathi, Daniel J DeAngelo, Kristen E Stevenson, et al.
American Journal of Respiratory and Critical Care Medicine|October 1, 2020
Addressing Disparities in Lung Cancer Screening Eligibility and Healthcare Access. An Official American Thoracic Society StatementM Patricia Rivera, Hormuzd A Katki, Nichole T Tanner, et al.
Blood|May 5, 2018
High <i>NPM1</i>-mutant allele burden at diagnosis predicts unfavorable outcomes in de novo AMLSanjay S Patel, Frank C Kuo, Christopher J Gibson, et al.
Pageof 17